Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autoimmune form of uveitis (disease).
Biomarker and diagnostic research for autoimmune uveitis has been reported in the published literature.
No approved treatments are currently available for autoimmune uveitis. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for autoimmune uveitis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for autoimmune uveitis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
1 clinical trial registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE1. Research is primarily sponsored by academic and government institutions.
233 publications have been identified in PubMed for autoimmune uveitis. Research spans Basic Science / Preclinical (55%), Review / Meta-Analysis (19%), and Epidemiology / Natural History (10%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 127 | 55% |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 1:16 AM UTC
Designated
Exclusivity End |
|---|
Designation Status |
|---|
AI-RSA | AI-RSA | AutoImmune, Inc. | 1992 | — | Withdrawn |
Gene therapy approaches for autoimmune uveitis have been reported in the published literature.
1 trial found
Research summaries | 45 | 19% |
Disease patterns and progression | 23 | 10% |
New treatment approaches | 19 | 8% |
Patient case studies | 10 | 4% |
Testing and diagnosis research | 8 | 3% |
Clinical study results | 1 | 0% |
Wang D (2026). [PMID: 42061599](https://pubmed.ncbi.nlm.nih.gov/42061599/). *Exp Eye Res*. [Basic Science / Preclinical]
Mukundan A (2026). [PMID: 41316839](https://pubmed.ncbi.nlm.nih.gov/41316839/). *Ocul Immunol Inflamm*. [Review / Meta-Analysis]
Shah SS (2026). [PMID: 34662020](https://pubmed.ncbi.nlm.nih.gov/34662020/). *Unknown Journal*. [Case Report / Case Series]
Moshirfar M (2026). [PMID: 32809317](https://pubmed.ncbi.nlm.nih.gov/32809317/). *Unknown Journal*. [Basic Science / Preclinical]
Zhou Y (2026). [PMID: 41851677](https://pubmed.ncbi.nlm.nih.gov/41851677/). *BMC Ophthalmol*. [Case Report / Case Series]
Foeldvari I (2026). [PMID: 41638996](https://pubmed.ncbi.nlm.nih.gov/41638996/). *Best Pract Res Clin Rheumatol*. [Review / Meta-Analysis]
Shi L (2026). [PMID: 41392486](https://pubmed.ncbi.nlm.nih.gov/41392486/). *Curr Eye Res*. [Basic Science / Preclinical]
Zloh M (2026). [PMID: 41643835](https://pubmed.ncbi.nlm.nih.gov/41643835/). *Exp Eye Res*. [Basic Science / Preclinical]
Gu J (2026). [PMID: 41674301](https://pubmed.ncbi.nlm.nih.gov/41674301/). *Redox report : communications in free radical research*. [Basic Science / Preclinical]
Hatemi G (2026). [PMID: 41876291](https://pubmed.ncbi.nlm.nih.gov/41876291/). *Ann Rheum Dis*. [Review / Meta-Analysis]